Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings from O.E. Young and co-authors broaden understanding of breast cancer
May 8th, 2008
According to a study from Scotland, "Fulvestrant (Faslodex (TM)) is a pure anti-oestrogen that reduces markers of hormone sensitivity and proliferation in postmenopausal women with oestrogen-receptor (ER)-positive breast cancer. This randomised trial compared the effects on the tumors of a single dose of 750 mg fulvestrant to those of daily tamoxifen (20 mg) taken 14-16 days prior to surgery in 60 premenopausal women with ER-positive primary breast cancer." "There were statistically significant falls in the expression of ER and Ki67 levels compared to the baseline with both drugs. Both drugs caused a decrease in PgR expression from baseline but this was only...
Source: Women's Health Weekly (2008-05-08)
|
